Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

Florence Ader; Maude Bouscambert-Duchamp; Maja Hites; Bernd Lamprecht; et al.

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

Florence Ader
, Maude Bouscambert-Duchamp
, Maja Hites
, Bernd Lamprecht
, et al.

Department of Internal Medicine 4 - Pneumology and Infectious Diseases

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	209-221
Number of pages	13
Journal	Lancet Infectious Diseases
Volume	22
Issue number	2
Publication status	Published - Feb 2022

Fields of science

302030 Internal medicine
302068 Pulmology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{8624d055a12e4ad69695797c02061da3,

title = "Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial",

author = "Florence Ader and Maude Bouscambert-Duchamp and Maja Hites and Bernd Lamprecht and \{et al.\}",

year = "2022",

month = feb,

language = "English",

volume = "22",

pages = "209--221",

journal = "Lancet Infectious Diseases",

number = "2",

}

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. / Ader, Florence; Bouscambert-Duchamp, Maude; Hites, Maja et al.
In: Lancet Infectious Diseases, Vol. 22, No. 2, 02.2022, p. 209-221.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy)

T2 - a phase 3, randomised, controlled, open-label trial

AU - Ader, Florence

AU - Bouscambert-Duchamp, Maude

AU - Hites, Maja

AU - Lamprecht, Bernd

AU - et al., null

PY - 2022/2

Y1 - 2022/2

UR - https://www.scopus.com/pages/publications/85123728033

M3 - Article

C2 - 34534511

VL - 22

SP - 209

EP - 221

JO - Lancet Infectious Diseases

JF - Lancet Infectious Diseases

IS - 2

ER -

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

Fields of science

UN SDGs

Other files and links

Cite this